Fulgent Genetics, Inc.
FLGTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How FLGT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FID007 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Frequently asked questions
What is in Fulgent Genetics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fulgent Genetics, Inc.'s (FLGT) pipeline across Phase 2. Its lead program is FID007 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fulgent Genetics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Fulgent Genetics, Inc. (FLGT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FLGT biotech catalysts?→
Add FLGT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fulgent Genetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.